Zhongzhi Pharmaceutical Holdings (HKG:3737) signed a $3 million investment agreement with US-based GABAeron, acquiring 11.5% of the latter's preferred stock, according to a Monday filing with the Hong Kong bourse.
GABAeron specializes in innovative therapies for Alzheimer's disease using stem-cell-derived interneurons to restore neural networks. The partnership aims to support clinical trials for Alzheimer's treatment targeting the apolipoprotein E4 gene.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.